Anticholinergic Burden and Cognitive Health in Older Adults
Summary
The anticholinergic burden refers to the overall load imposed by medications that block acetylcholine, a neurotransmitter integral to memory, attention and executive function. In later life, this burden often accumulates through polypharmacy—most notably antihistamines, bladder antispasmodics, certain antidepressants and antipsychotics—compounding age-related declines in cholinergic neurotransmission. Elevated anticholinergic burden has been associated with slower processing speed, impaired short-term recall, increased incidence of delirium and a heightened risk of progression to dementia. At a cellular level, antagonism of central muscarinic receptors disrupts synaptic plasticity and neuronal network integrity. Clinically, precise assessment of anticholinergic exposure underpins de-prescribing initiatives aimed at preserving functional independence, reducing hospital admissions and safeguarding quality of life in vulnerable older populations.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Anticholinergic Burden and Cognitive Health in Older Adults publication trend
The graph below shows the total number of articles in anticholinergic burden and cognitive health in older adults across all publications each year (not limited to Nature Index journals).
Technical terms
Anticholinergic burden: The cumulative pharmacological effect of medications that antagonise acetylcholine transmission.
Muscarinic receptor: A subtype of cholinergic receptor mediating central and peripheral nervous system functions.
Drug Burden Index: A composite measure quantifying cumulative exposure to anticholinergic and sedative medications.
Mini‐Mental State Examination: A brief screening tool for assessing cognitive performance across several domains.
Blood–brain barrier: The physiological barrier regulating molecular passage between the bloodstream and brain tissue.
References
- Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study. Alzheimer's Research & Therapy (2024).
- A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity. Pharmaceutics (2023).
- Increasing prevalence of anticholinergic medication use in older people in England over 20 years: cognitive function and ageing study I and II. BMC Geriatrics (2020).
- Anticholinergic Drug Burden and Delirium: A Systematic Review. Journal of the American Medical Directors Association (2020).
- Anticholinergic Drugs in Geriatric Psychopharmacology. Frontiers in Neuroscience (2019).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.